Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma	B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 1 / Phase 2	2026-10-09		NCT05326243

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Pell Bio-Med Technology Co., Ltd.	2

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Chi Mei Medical Center	Tainan	Taiwan	9
Kaohsiung Medical University Chung-Ho Memorial Hospital	Kaohsiung City	Taiwan	11
National Taiwan University Hospital	Taipei	Taiwan	6
Taipei Medical University - Taipei Medical University Hospital	Taipei	Taiwan	2
Taipei Veterans General Hospital	Taipei	Taiwan	27